Pioneering treatments

A surgical procedure to repair an aorta root affected by Marfan Syndrome

Cytoreductive surgery and HIPEC treatment at HCA Healthcare UK. HIPEC treatment is an innovative and complex procedure used during surgery to treat colorectal cancer which has spread to the lining of the abdomen (peritoneum).

Also known as AHSCT or HSCT, this treatment reboots the immune system to halt the progression of MS.

A groundbreaking immunotherapy that uses your own immune system to target and eliminate cancer cells. 

At HCA Healthcare UK, we combine clinical expertise with state-of-the-art facilities, to deliver this complex and innovative treatment with safety and care.

Less invasive, minimal access surgical technique for mitral and aortic valves, it can be an alternative for open heart surgery (sternotomy). The technique provides more options for patients and can help them achieve a better quality of life more quickly, along with less pain and scarring.

ENDOSCOPIC SKULL BASE SURGERY

If you have a tumour which can be treated with minimally invasive skull base surgery, our surgeons can treat you

A spinal fusion procedure that fuses the front and back section of the spine through a posterior approach. If you have nerve or disc problems in your spine, our consultants can treat you with minimally invasive fusion surgery.

HCA UK’s The Harborne Hospital in Birmingham has become the first facility in the West Midlands to treat a lung cancer patient using bispecific antibody therapy, a significant advancement in the treatment of solid tumours, highlighting the hospital’s growing role in cutting-edge cancer care.

HCA Healthcare UK has announced that it has treated a metastatic lung cancer patient with tumour-infiltrating lymphocyte (TIL) therapy for the first time as part of a clinical trial at its research arm, Sarah Cannon Research Institute UK. 

The ground-breaking cellular therapy treatment represents a significant milestone in targeting advanced cancer, marking HCA UK's continued leadership in bringing cutting-edge immunotherapy treatments to patients in the UK.

Leading private healthcare provider HCA Healthcare UK has announced that it is offering amyloid-targeting therapies for patients diagnosed with early-stage Alzheimer's disease. The therapies available include lecanemab and donanemab - the first two disease-modifying treatments for Alzheimer’s disease licensed for use in Great Britain.